Spring Mountain Capital

Spring Mountain Capital is a growth equity investment firm established in 2001 and based in New York, New York. The firm specializes in providing expansion capital to companies that are leveraging breakthrough innovations and responding to significant market changes. It primarily invests in the U.S. lower middle market, focusing on sectors with high growth potential, including enterprise software, technology-enabled services, digital health, and healthcare services. Additionally, Spring Mountain Capital explores opportunities in life sciences, cybersecurity, e-commerce, impact investing, and virtual reality. As a Registered Investment Adviser, the firm aims to support companies that are positioned for substantial growth in a rapidly evolving economic landscape.

Jason Orchard

Managing Director and Head of Total Return

Kenneth Soll

Vice President

Raymond Wong

Managing Director, Head of Private Equity

42 past transactions

Thentia Cloud

Series B in 2022
Thentia Corporation is an industry leader in using proprietary technology to help regulatory bodies efficiently fulfill their regulatory obligations. Thentia services a wide variety of clients throughout Canada and the United States using cutting-edge software and industry-leading expertise in regulatory standards.

Genomenon

Series B in 2022
Genomenon develops software tools to rapidly and autonomously prioritize data points for decision-making. It revolutionizes the way genetic diagnoses and discoveries are made. The company’s suite of diagnostic and discovery tools enable physicians, pharma, and researchers to quickly and accurately identify disease-causing variants from genomic-sequencing datasets. It was founded in 2014 and is headquartered in Ann Arbor, Michigan.

EverWash

Series B in 2022
EverWash operates a cloud-based subscription management platform designed specifically for the car wash industry. The company partners with local car washes to offer unlimited-use, monthly membership plans, allowing customers to wash their vehicles as frequently as desired. Its software as a service (SaaS) platform streamlines the membership sales and marketing processes, automating customer enrollment, billing, and revenue recognition. By optimizing these operations, EverWash helps its partners attract and retain more monthly members while enhancing revenue growth and reducing operational costs. This approach positions EverWash as a valuable resource for car wash businesses aiming to improve customer engagement and profitability.

Eyrus

Series A in 2022
Eyrus, a workforce visibility platform for construction, automates the collection of workforce data, and allows project teams to accurately enhance attendance, timekeeping, safety, and security data in real time. Simply implement Eyrus at the time of workforce registration, capturing OSHA, health and safety, and equipment training information through an easy to set-up worker profile. Then, through the use of IoT and mobile devices, understand the interaction of the workforce throughout the worksite during the course of construction, or jobsite management, with access control, real-time alert systems for evacuation, and metrics for compliance reporting. All in an easy to use cloud-based platform. The data collected can then help with schedule forecast analytics, understanding delays before they occur, and creates jobsite intelligence enhancing decision making, and project planning.

Koneksa Health

Series C in 2022
Koneksa Health is a healthcare data analytics company that helps researchers incorporate emerging technologies (bio-sensors, activity trackers, mobile-based questionnaires, etc.) into their clinical studies. Their Koneksa Compare software dashboard enables the collection, visualization, and analysis of these patient-generated data sets. Koneksa currently supports academic and life sciences researchers, expands the universe of data that can be analyzed while also removing subjective characteristics from clinical endpoints. It was founded in 2015 and is based in New York, United States.

Ankyra

Series B in 2021
Ankyra is a biotech company developing anchored immunotherapy for cancer treatments. Systemic dosing of these potent immune stimulants is restricted due to widespread immune activation and toxicity. When cytokines are injected into tumor tissue, they localize specifically and persistently, causing intense hot spots of inflammation that activate an anti-tumor immune response. Ankyra used its Anchored Immunotherapy Platform to develop ANK-101, a stable complex of a modified IL-12 cytokine with aluminum hydroxide (Alhydrogel) to overcome the limitations of traditional cytokine therapeutics. Alhydrogel, an FDA-approved adjuvant for use in human and veterinary vaccines, acts as a scaffold to locally retain the potent activity of IL-12 after intratumoral administration, improving its therapeutic window. Ankyra's mission is to optimize the impact of anchored immunotherapy to improve the lives of patients with cancer.

Aware

Series C in 2021
Aware is a cloud intelligence platform that adopts the latest advancements in cognitive computing, artificial intelligence, and behavioral analytics to amplify enterprise value by monitoring the social graph. They harness the power of their platform’s insights into human behavior and interactivity to create great value for the enterprise.

RepairSmith

Series B in 2021
RepairSmith delivers car repair and maintenance services with convenient options for car owners. Its services allow car owners to get their repair delivered to their driveway or drop it off with an upfront price, online booking, after-hours support, and a full warranty. The company was founded in 2018 and is headquartered in El Segundo, California.

Allyx Therapeutics

Venture Round in 2021
Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug capable of delivering a disease-modifying approach and preserving cognition in patients.

Thentia Cloud

Series B in 2021
Thentia Corporation is an industry leader in using proprietary technology to help regulatory bodies efficiently fulfill their regulatory obligations. Thentia services a wide variety of clients throughout Canada and the United States using cutting-edge software and industry-leading expertise in regulatory standards.

Aware

Series B in 2020
Aware is a cloud intelligence platform that adopts the latest advancements in cognitive computing, artificial intelligence, and behavioral analytics to amplify enterprise value by monitoring the social graph. They harness the power of their platform’s insights into human behavior and interactivity to create great value for the enterprise.

Koneksa Health

Series B in 2020
Koneksa Health is a healthcare data analytics company that helps researchers incorporate emerging technologies (bio-sensors, activity trackers, mobile-based questionnaires, etc.) into their clinical studies. Their Koneksa Compare software dashboard enables the collection, visualization, and analysis of these patient-generated data sets. Koneksa currently supports academic and life sciences researchers, expands the universe of data that can be analyzed while also removing subjective characteristics from clinical endpoints. It was founded in 2015 and is based in New York, United States.

Maven

Series C in 2020
Maven Clinic operates an on-demand digital care clinic focused on supporting mothers and families during conception, pregnancy, and postpartum stages. The clinic provides access to video appointments and private messaging with a network of women's and family health practitioners. Its services cover various needs, including IVF, egg freezing, pregnancy, postpartum support, adoption, surrogacy, and loss. Additionally, Maven Clinic offers career coaching, support, and tailored training for human resources. The company serves individuals, employers, and healthcare professionals, aiming to enhance healthcare experiences and outcomes for families. Founded in 2014 and headquartered in New York City, Maven Clinic is dedicated to delivering accessible and comprehensive care solutions.

IsoPlexis

Series C in 2020
IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions. The company was founded in 2013 and is headquartered in Branford, Connecticut.

IsoPlexis

Series C in 2019
IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions. The company was founded in 2013 and is headquartered in Branford, Connecticut.

Keen Decision Systems

Series A in 2019
Keen Decision Systems is a developer of software-as-a-service used to help marketers make courageous, data-driven decisions. Its technology is a real-time resource that accurately calculates financial contribution across all marketing channels that enable marketers to maximize profitability, maximize revenue, or optimize marketing investments within a fixed budget.

Maven Clinic

Series B in 2018
Maven Clinic operates an on-demand digital care clinic that assists mothers and families during conception, throughout pregnancy, and postpartum. It offers video appointments and private messaging with its proprietary women's and family health practitioner network, as well as a family benefits platform. Maven Clinic offers its services for IVF and egg-freezing tracks, pregnancy, postpartum, partner, adoption, surrogacy, and loss tracks, and career coaching and support, and customized manager training for HR. It serves individuals, employers, and healthcare professionals. It was founded in 2014 by Katherine Ryder and is headquartered in New York City.

RiskSense

Series B in 2018
RiskSense®, Inc. provides vulnerability prioritization and management to measure and control cybersecurity risk. The cloud-based RiskSense platform uses a foundation of risk-based scoring, analytics, and technology-accelerated pen testing to identify critical security weaknesses with corresponding remediation action plans, dramatically improving security and IT team efficiency and effectiveness. The company delivers a fully-informed picture of group, department, and organizational cybersecurity risk with our credit-like RiskSense Security Score (RS3). The RiskSense platform continuously correlates customer infrastructure with comprehensive internal and external vulnerability data, threat intelligence, human pen test findings, and business asset criticality to measure risk, provide early warning of weaponization, predict attacks, and prioritize remediation activities to achieve security risk goals

Vergent Bioscience

Series A in 2018
While the complete removal of residual cancer at the tumor margins during the surgical resection of solid tumors is closely linked with improved cure rates, it is often difficult for even experienced surgeons to distinguish cancerous tissue from normal tissue. Visual differentiation is needed at the cellular level. Vergent's molecularly-targeted imaging molecule, VGT-309, binds to enzymes that are overexpressed in tumor tissue, activating a brightly fluorescing dye. This proprietary molecule can identify and bind to multiple cancers including lung, breast, ovarian, colorectal, and brain, among others. When injected prior to surgery, VGT-309 “lights up” cancerous tissue and gives the surgeon a clear visual guide for the removal procedure. Vergent’s approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic surgery procedures, while uniquely retaining the pricing flexibility required for success in a value-based healthcare system.

ReNetX Bio

Series A in 2018
ReNetX Bio first-in-class therapeutics to treat injury and damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI)and glaucoma.

Home Captain

Series A in 2018
Home Captain is providing tools, services, and the data that lenders and homebuyers need in a competitive and ever-changing digital world. Within its suite of products and services, Home Captain offers a web and mobile MLS-integrated home search app, an AI-powered chatbot, multiple world-class real estate concierge services, portfolio retention services, and a patent-pending agent matching technology.

180 Health Partners

Series B in 2018
180 Health Partners provides multi-modal care coordination between opioid-addicted mothers and healthcare providers.180 Health Partners works with expecting mothers to turn the tide of prenatal substance use resulting in the delivery of healthy thriving babies.

IsoPlexis

Series B in 2017
IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions. The company was founded in 2013 and is headquartered in Branford, Connecticut.

Maven

Series A in 2017
Maven Clinic operates an on-demand digital care clinic focused on supporting mothers and families during conception, pregnancy, and postpartum stages. The clinic provides access to video appointments and private messaging with a network of women's and family health practitioners. Its services cover various needs, including IVF, egg freezing, pregnancy, postpartum support, adoption, surrogacy, and loss. Additionally, Maven Clinic offers career coaching, support, and tailored training for human resources. The company serves individuals, employers, and healthcare professionals, aiming to enhance healthcare experiences and outcomes for families. Founded in 2014 and headquartered in New York City, Maven Clinic is dedicated to delivering accessible and comprehensive care solutions.

SimpleReach

Series B in 2017
SimpleReach is the #1 way for brands to measure and improve content ROI. By bringing together hundreds of data sources across websites, social channels, and publishers into the world's largest content data cloud, SimpleReach enables brands to understand how their content drives business outcomes everywhere. Leading content marketers like Intel, Chase, and Home Depot rely on the SimpleReach platform to generate actionable insights that improve the impact of their content creation and distribution. Learn more at www.simplereach.com

Doctor.com

Series A in 2017
Doctor.com is the first marketing automation platform purpose-built for healthcare organizations. We've been first to market with leading reputation management and patient acquisition services including ProfileSync, ProfilePromote, and the Doctor.com ReviewHub, which was the subject of a case study on the Google Enterprise blog. All Doctor.com services connect to a proprietary network of leading consumer health and local business sites that collectively reach over 100M patients monthly, giving our clients an unrivaled advantage in their online marketing. As one of the fastest-growing SaaS companies in the healthcare vertical, they're fortunate to be backed by world-class investors and supported by a truly exceptional team.

Prevalent

Series B in 2016
Prevalent takes the pain out of third-party risk management (TPRM). Companies use our software and services to eliminate the security and compliance exposures that come from working with vendors and suppliers throughout the third-party lifecycle. Our customers benefit from a flexible, hybrid approach to TPRM, where they not only gain solutions tailored to their needs but also realize a rapid return on investment. Regardless of where they start, we help our customers stop the pain, make informed decisions, and adapt and mature their TPRM programs over time.

Oncoceutics

Series A in 2015
Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The company’s leadership team represents a group of drug development executives with unparalleled success in the industry. Central to Oncoceutics’ scientific and technology base is a focus on drug discovery that engages natural potent tumor suppressor pathways. The first lead compound that came out of this program is ONC201, a small molecule that possesses significant anti-tumor activity in a number of different types of human cancer through a unique mechanism of action. The compelling preclinical efficacy and safety of ONC201 along with its favorable chemical properties offer a high potential for safe and meaningful therapeutic benefit to cancer patients in numerous clinical settings. Clinical lead indications for ONC201 are being evaluated in a series of clinical trials that are in various stages of initiation at leading cancer centers around the world. Central to Oncoceutics’ scientific and technology base is a focus on drug discovery that engages natural potent tumor suppressor pathways. The first lead compound that came out of this program is ONC201, a small molecule that possesses significant anti tumor activity in a number of different types of human cancer through a unique mechanism of action. ONC201 induces a striking cytotoxic response within tumors by engaging highly conserved apoptotic response mechanisms. ONC201s unique ability to engage these mechanisms selectively in tumors while sparing normal cells provides a wide spectrum of activity in early and late stage cancers that is accompanied by an attractive safety profile. The compelling preclinical efficacy and safety of ONC201 along with its favorable chemical properties offer a high potential for safe and meaningful therapeutic benefit to cancer patients in numerous clinical settings.

Ziften Technologies

Series C in 2015
Ziften is a privately funded endpoint security company based in Austin, Texas. The organization provides a cloud-delivered endpoint protection platform that prevents attacks on endpoints – laptops, desktops, servers, and cloud – with capabilities including advanced protection, endpoint detection and response, and security posture analysis.

Activate Healthcare

Venture Round in 2015
Activate Healthcare engages patients to take charge of their own health by delivering proactive, preventive primary care at or near an employer’s location. Predictive modeling tools are leveraged to identify high-risk patients so the medical staff can engage with these patients to proactively reduce their health risks and guide them in managing their health. Activate Healthcare provides a comprehensive process to engage and empower patients to manage their health. It was founded in 2009 and headquartered in Indianapolis, Indiana.

OpenSlate

Series A in 2015
OpenSlate is the premier global source of brand safety and contextual analytics for digital video content. Founded in 2012 by CEO Mike Henry, OpenSlate is the only company that can comprehensively measure the brand suitability of digital content for advertisers and also identifies the most-effective content for their campaigns. They provide advertisers with brand-suitable targeting solutions, as opposed to simply monitoring for after-the-fact exposure to inappropriate content. Their technology, data expertise, and proprietary analytics were developed specifically to support the needs of the world’s largest digital video platform — YouTube — and are extensible to all video content across the web. Our platform is used by every major advertising holding company, as well as the world’s largest advertisers. OpenSlate was founded in 2011 and is headquartered in New York, NY, USA.

Oncoceutics

Venture Round in 2014
Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The company’s leadership team represents a group of drug development executives with unparalleled success in the industry. Central to Oncoceutics’ scientific and technology base is a focus on drug discovery that engages natural potent tumor suppressor pathways. The first lead compound that came out of this program is ONC201, a small molecule that possesses significant anti-tumor activity in a number of different types of human cancer through a unique mechanism of action. The compelling preclinical efficacy and safety of ONC201 along with its favorable chemical properties offer a high potential for safe and meaningful therapeutic benefit to cancer patients in numerous clinical settings. Clinical lead indications for ONC201 are being evaluated in a series of clinical trials that are in various stages of initiation at leading cancer centers around the world. Central to Oncoceutics’ scientific and technology base is a focus on drug discovery that engages natural potent tumor suppressor pathways. The first lead compound that came out of this program is ONC201, a small molecule that possesses significant anti tumor activity in a number of different types of human cancer through a unique mechanism of action. ONC201 induces a striking cytotoxic response within tumors by engaging highly conserved apoptotic response mechanisms. ONC201s unique ability to engage these mechanisms selectively in tumors while sparing normal cells provides a wide spectrum of activity in early and late stage cancers that is accompanied by an attractive safety profile. The compelling preclinical efficacy and safety of ONC201 along with its favorable chemical properties offer a high potential for safe and meaningful therapeutic benefit to cancer patients in numerous clinical settings.

Activate Healthcare

Private Equity Round in 2014
Activate Healthcare engages patients to take charge of their own health by delivering proactive, preventive primary care at or near an employer’s location. Predictive modeling tools are leveraged to identify high-risk patients so the medical staff can engage with these patients to proactively reduce their health risks and guide them in managing their health. Activate Healthcare provides a comprehensive process to engage and empower patients to manage their health. It was founded in 2009 and headquartered in Indianapolis, Indiana.

IsoPlexis

Series A in 2014
IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions. The company was founded in 2013 and is headquartered in Branford, Connecticut.

HμREL

Series A in 2013
HμREL® Corporation is an early-stage bioanalytic tools company with operations based in Kenilworth and New Brunswick, New Jersey, USA. Robert Freedman serves as Chief Executive Officer. Martin Yarmush is the Company’s Chief Scientific Adviser.

WhipTail

Series C in 2012
WhipTail Technologies commercialized the first all-flash enterprise storage array to address performance issues in data centers. Installed worldwide in numerous mission critical database, virtualization, and online environments, WhipTail's solid-state storage dramatically reduces delays related to hard disk contention and access times, allowing servers to process more data in dramatically less time -- months to days, hours to minutes. Since 2009, customers have relied on WhipTail's flash-based arrays for extreme IOPS, bandwidth and latency, optimizing performance of key business functions and bringing modern performance demanding applications to life.

OpenSlate

Series A in 2012
OpenSlate is the premier global source of brand safety and contextual analytics for digital video content. Founded in 2012 by CEO Mike Henry, OpenSlate is the only company that can comprehensively measure the brand suitability of digital content for advertisers and also identifies the most-effective content for their campaigns. They provide advertisers with brand-suitable targeting solutions, as opposed to simply monitoring for after-the-fact exposure to inappropriate content. Their technology, data expertise, and proprietary analytics were developed specifically to support the needs of the world’s largest digital video platform — YouTube — and are extensible to all video content across the web. Our platform is used by every major advertising holding company, as well as the world’s largest advertisers. OpenSlate was founded in 2011 and is headquartered in New York, NY, USA.

WhipTail

Series B in 2012
WhipTail Technologies commercialized the first all-flash enterprise storage array to address performance issues in data centers. Installed worldwide in numerous mission critical database, virtualization, and online environments, WhipTail's solid-state storage dramatically reduces delays related to hard disk contention and access times, allowing servers to process more data in dramatically less time -- months to days, hours to minutes. Since 2009, customers have relied on WhipTail's flash-based arrays for extreme IOPS, bandwidth and latency, optimizing performance of key business functions and bringing modern performance demanding applications to life.

WhipTail

Series A in 2011
WhipTail Technologies commercialized the first all-flash enterprise storage array to address performance issues in data centers. Installed worldwide in numerous mission critical database, virtualization, and online environments, WhipTail's solid-state storage dramatically reduces delays related to hard disk contention and access times, allowing servers to process more data in dramatically less time -- months to days, hours to minutes. Since 2009, customers have relied on WhipTail's flash-based arrays for extreme IOPS, bandwidth and latency, optimizing performance of key business functions and bringing modern performance demanding applications to life.

NXTM

Private Equity Round in 2011
Led by a former senior MTV executive, NXTM powers the digital presence for superstars Taylor Swift, Justin Timberlake, and Lenny Kravitz. Via its platform WHOOZNXT, NXTM equips emerging artists with these same tools and top-tier exposure opportunities. With major media partnerships in television, radio, live venues, digital platforms, and more - WHOOZNXT is the only platform that rewards the online activity of artists with real-world exposure.

Coolerado

Series B in 2010
Coolerado designs, manufactures and markets super-energy-efficient air conditioning systems for light commercial and residential use, based on its proprietary, patented, and proven technology.

Perquest

Series B in 2007
Perquest is redefining workforce solutions through technology, service and process innovations. They are serious about service: Perquest is dedicated to making service their competitive advantage. They are committed to service at the highest levels of our organization, and have established a service culture, and tools, that allow us to live and breathe "service" every day. Specifically, they are integrated advanced customer relationship (CRM) technology into offering and made it accessible to everyone: employees, customers and partners. This enables maximum transparency between your organization and theirs; through highly secure Client Portal, you can contact Perquest and get a response within minutes. Perquest makes it easy: The company philosophy is exactly that: "Make it easy." That's why they deliver a mix of high-touch, full-service managed payroll and SaaS-based premier HR applications that are extremely easy to use — by anyone. The solutions are rock-solid: Reliability is the hallmark of Perquest workforce solutions. Market-proven to meet the demands of mid-size companies like yours, they deliver a single platform that integrates the workforce solutions you need with the CRM capabilities Perquest leverages to provide the utmost in service.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.